Inovio Pharmaceuticals Inc vs UDR Inc. Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.18 (market cap $103.19M), while UDR Inc. Common Stock trades at $33.9 (market cap $10.93B). The key difference: UDR Inc. Common Stock is far larger — about 105.9× Inovio Pharmaceuticals Inc's market cap, and UDR Inc. Common Stock pays a 5.12% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and UDR Inc. Common Stock for 0 Days on average.
| INO | UDR | |
|---|---|---|
Market Cap | $103.19M | $10.93B |
Volume | 8,461,580 | 2,607,837 |
Sector | Health | Real Estate |
52-Week High | $2.60 | $41.24 |
52-Week Low | $0.66 | $33.27 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $74.52M | $16.96B |
Dividend Yield | — | 5.12% |
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.986, down 10.77% in the last session, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis. Analyst consensus remains positive with a $2.75 price target despite negative profitability metrics.
The stock presents high-risk biotech speculation with potential upside dependent on FDA approval. Current valuation metrics (P/S 961.51) reflect speculative optimism rather than fundamentals. Major risks include cash burn (-$21.5M net cash flow), regulatory uncertainty, and competitive pressures. Successful commercialization of INO-3107 is critical for viability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →UDR, Inc. is a self-administered real estate investment trust that owns, operates, develops, and redevelops multifamily apartment communities across targeted US markets. The company generates income primarily through leasing apartment homes, with a portfolio concentrated in coastal and Sunbelt metropolitan areas.
Read more on UDR →